FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094
The FDA has approved QLONILIK, containing Clonidine Hydrochloride, under NDA221094.
Published: August 2, 2026
Updated: August 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antihypertensive
Asset: QLONILIK
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
QLONILIK
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of QLONILIK introduces a new therapeutic option in the antihypertensive market, which could disrupt existing treatment paradigms. Strategic teams must evaluate competitive positioning and potential partnerships to leverage this new entry effectively.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake and any competitive responses from established antihypertensive brands.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.